Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Inks microRNA Drugs Collaboration with AstraZeneca


Regulus Therapeutics this week announced that it has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics against three exclusive targets.

The preclinical targets, Regulus said, are focused on cardiovascular and metabolic diseases and cancer. The company said its work on miR-33 for the treatment of atherosclerosis is included in the arrangement.

Regulus acquired the exclusive rights to miR-33-related intellectual property early last year (GSN 3/31/2011). Notably, miRNA drug firm Santaris Pharma is also developing miR-33-targeting therapies for cardiovascular disorders with its own IP (GSN 3/3/2011).

AstraZeneca will make an initial $28 million payment to Regulus, which includes an equity investment. Regulus also stands to receive milestones and royalties.

Regulus will be responsible for preclinical development of the drugs, while AstraZeneca will handle clinical and commercialization efforts.

Additional terms were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.